Eisai and Biogen launch LEQEMBI for Alzheimer’s in China

28 Jun 2024
·
Deals
www.pharmaceutical-technology.com
Drug ApprovalPhase 3Clinical Result
Eisai and Biogen launch LEQEMBI for Alzheimer’s in China
Preview
Source: Pharmaceutical Technology
The treatment obtained approval in January 2024 for mild cognitive impairment due to AD and mild AD dementia. Credit: Ground Picture/ Shutterstock.
Eisai and Biogen have announced the introduction of LEQEMBI (lecanemab) for the treatment of Alzheimer’s disease (AD) in China.
The treatment obtained approval in January 2024 for mild cognitive impairment due to AD and mild AD dementia.
China becomes the third country to offer LEQEMBI, following its introduction in the US and Japan.
A monoclonal antibody, LEQEMBI is designed to target and reduce amyloid-beta aggregates in the brain, a characteristic of AD.
The product is specifically engineered to bind to both soluble and insoluble amyloid-beta aggregates, which are implicated in the pathogenesis of Alzheimer’s.
See Also:Verona scores FDA approval for Ohtuvayre as COPD maintenance therapy
Eisai and Biogen launch LEQEMBI for Alzheimer’s in China
Preview
Source: Pharmaceutical Technology
FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market
Eisai and Biogen launch LEQEMBI for Alzheimer’s in China
Preview
Source: Pharmaceutical Technology
It is the only approved treatment that has demonstrated efficacy in slowing the progression of the disease by impacting these aggregates.
Eisai is responsible for the distribution of LEQEMBI in China and is actively engaged in creating awareness and diagnosis pathways for early AD that integrate both digital and traditional services.
The company’s strategy includes partnerships with health insurance companies, health check-up providers and nursing homes to enhance disease awareness and promote early screening.
It is also pioneering the use of blood biomarkers for definitive early AD diagnosis.
Initially, LEQEMBI will be available in China’s private market.
Eisai leads the global development and regulatory submissions for LEQEMBI, while both companies are involved in its co-commercialisation and promotion. Final decision-making authority rests with Eisai.
The approval for LEQEMBI in the US was underpinned by results from Eisai’s Phase III Clarity AD trial.
The trial met its primary endpoint, showing a 27% reduction in clinical decline on the Clinical Dementia Rating Sum of Boxes (CDR-SB) at 18 months when compared to a placebo.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.